Bioxytran (BIXT) Other Accumulated Expenses (2021 - 2026)

Bioxytran (BIXT) posted Other Accumulated Expenses of $155160.0 for Q1 2026, up 35.47% sequentially from $114534.0 in Q4 2025.

Bioxytran (BIXT) Other Accumulated Expenses (2021 - 2026) Analysis & Trends

Bioxytran has reported Other Accumulated Expenses for 6 years, with the latest figure at $155160.0 in Q1 2026.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $155160.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155160.0 (changed N/A YoY) and the FY2025 annual result came in at $114534.0, up 53.73% from the prior year.
Other Accumulated Expenses grew to $155160.0 in Q1 2026 per BIXT's latest filing, from $114534.0 in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $262500.0 in Q2 2022 and troughed at $2000.0 in Q4 2023.
A 5-year average of $110568.3 and a median of $94519.0 in 2024 frame the typical range for Other Accumulated Expenses.
The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses plunged 98.89% in 2023, then soared 3625.2% in 2024.
Over 5 years, Other Accumulated Expenses stood at $180557.0 in 2022, then slumped by 98.89% to $2000.0 in 2023, then jumped by 3625.2% to $74504.0 in 2024, then surged by 53.73% to $114534.0 in 2025, then jumped by 35.47% to $155160.0 in 2026.
According to Business Quant data, Other Accumulated Expenses over the past three periods registered $155160.0, $114534.0, and $57267.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Bioxytran	2.52 Mn	2.27 Mn	-

Download Data